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Introduction
Type 1 diabetes (T1D) is associated with microvascular 
and macrovascular complications [1]. 
Duration of diabetes, poor glycaemic control, high 
blood pressure and proteinuria are reported risk 
factors contributing to the development of diabetes 
related complications [1-3]. Diabetic retinopathy 
(DR) is a progressive, potentially sight threatening 
disease of the retinal neuro-vasculature associated with 
diabetes. Diabetic retinopathy develops due to chronic 
hyperglycaemia which causes damage to the retinal 
capillaries, leading to capillary blockage and leakage. 
Diabetic retinopathy is asymptomatic until the advanced 
stages and if undiagnosed and remains untreated, can 
progress to severe visual loss. Globally it is the leading 
cause of blindness among the working age population 
(aged 16-64 years) and the commonest complication of 
T1D [4]. However, in the UK diabetic retinopathy has been 
overtaken by hereditary retinal disease as the leading cause 
of blindness [5,6]. This is largely due to the introduction 
of screening for diabetic retinopathy and improvement 
in the management of diabetes, and more effective 
ophthalmological management. Early complications of 
DR have been reported in adolescents with T1D between 
2 to 5 years diabetes duration despite more intensive 
management [7]. 
Comparative Data and Prevalence
Prevalence of DR is variable as reported in several 
studies. This variability is due to differences in study 
populations such as age, type of diabetes, and location 
i.e. community or hospital setting, methods of detecting 
diabetic retinopathy fundoscopy, digital photography 
and slit lamp examination and grading protocols used. 
The global prevalence of DR was 34.6% from a pooled 
analysis of 22,896 individuals with diabetes [8], this was 
updated in the International Diabetes Federation (IDF) 
atlas 9th edition with any DR reported to be 27.0%, non-
proliferative DR 25.2%, proliferative DR 1.4% and DME 
4.6% between 2015 and 2019 [9]. The lowest prevalence 
of any DR was reported in South East Asia at 12.5% and 
highest in the Western Pacific at 36.3%. The prevalence of 
DR in children and young people with diabetes has been 
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reported to range between 2.3% and 57.6% [10-25]. In 
Wales between 2003 and 2018 in 4,172 people diagnosed 
with T1D up to the age of 18 years eligible for screening 
(in those with T1D from 12 years) with gradable retinal 
photographs, the prevalence of background DR was 26.7%, 
referable DR 10.7% and proliferative DR 4.1% [26]. 
In the recent National Paediatric Diabetes Audit (NPDA) 
2018/19 report for the United Kingdom, there were 28,597 
(52% male) children and young people with T1D [27]. The 
NPDA only records eye screening as normal and abnormal 
with the majority of the abnormal results being due to 
background DR. There were 11,431 aged 12 years or older 
with a valid eye screening examination. DR was found in 
13.1% of young people (0-18 years old) with T1D in England 
and Wales with variation between country (13.4% England 
and 7.6% Wales) and regions (7.8% West Midlands and 
17.5% East Midlands). The prevalence of abnormal DR in 
the current NPDA 2018/19 report was higher compared 
to the previously published 2017/18 report when it was 
12.8% but lower than the 2016/17 and 2015/16 reports at 
14.8 and 15.3% respectively.
Prevalence of DR has been shown to be rare in young 
people <10 years but increases with increasing age. The 
Wisconsin study (WESDR) [4] which was the landmark 
study of DR reported the prevalence of DR in people 
diagnosed with T1D before the age of 30 years. WESDR 
found the prevalence of DR in those aged 10-14 years was 
2% and in those aged 15-19 years was 10%. The youngest 
age at which DR has been observed was 5 years, [20] and 
the youngest age at which sight threatening DR reported 
was 15 years, [4] with only five cases of sight threatening 
DR reported in children <18 years [4,20]. However, in a 
study of 370 children with diabetes aged <18 years, no 
cases of DR were found [23]. In the NPDA, the risk of DR 
increased with age and was highest amongst adolescent 
females with 6.2% of boys and 5.6% of girls aged 12 years 
rising to 21.7% and 30.4% of boys and girls respectively 
aged 18 years having abnormal screening results [27].
Risk Factors for DR
There are many risk factors that have been shown to 
be associated with the development and progression of 
DR; duration of diabetes, hyperglycaemia, hypertension, 
ethnicity, dyslipidaemia, puberty, pregnancy, proteinuria, 
genetics, obesity, alcohol consumption, inflammation 
and endothelial dysfunction. However, the evidence 
is inconsistent, and the mechanism of action is less 
well known [28]. Some of these risk factors are further 
discussed here.
Duration of diabetes has been shown in many studies 
to be a risk factor for the development of DR, with the 
early Wisconsin study showing that 2% of those with a 
duration of diabetes <2 years had DR increasing to 98% 
after 15 years and 25% having proliferative DR [4]. A 
few other studies have also reported DR in those with a 
duration of T1D <2 years [29-32]. This was also seen in 
Wales where 10% of those with a duration of diabetes of 2 
years had DR. However, other studies have shown no DR 
below a duration of diabetes of 5 years [26]. In the NPDA 
4.7% of those with T1D for less than 1 year had abnormal 
screenings increasing to 14.7% at 5-9 years and 33.5% after 
15 years or longer [27].
Hyperglycaemia has long been associated with an 
increased risk of developing DR as seen in the landmark 
DCCT study as well as many other studies in the UK [33,34], 
Europe [35,36] and the US [37,38]. The age standardised 
prevalence of DR in the global meta-analysis increased 
with increasing HbA1c from 17.9% at ≤ 53mmol/mol to 
51.2% at HbA1c >75mmol/mol [8]. In the NPDA young 
people with T1D and higher HbA1c had an increased risk 
of abnormal eye screening [27]. In those with a HbA1c ≥ 69 
mmol abnormal screening was seen in >50%, compared 
to >35% with a normal screening. In those with abnormal 
screening 30.1% had HbA1c levels above 80 mmol/mol 
compared to 16.4% of those with normal screening. The 
introduction of intensive insulin therapy to optimise 
glycaemic management in children has been observed to 
have a beneficial effect on DR in multiple studies [3,39,40]. 
In Australia [3], comparing the prevalence of DR between 
1990-1994 and 2005-2009 and Wisconsin[41] comparing 
20 year DR rates have both observed a decrease in 
DR overtime, which has been attributed in part to the 
intensification of diabetes insulin regimens. The benefit 
of such intensive management in the adolescent years 
remains evident many 44 years later (legacy effect) even 
when HbA1c values deteriorate, becoming similar to those 
undergoing conventional insulin therapy [40].
Hypertension has also been shown to be a risk factor for 
DR. The age standardised prevalence of DR in the global 
meta-analysis increased with increasing blood pressure 
from 30.8% at blood pressure of ≤ 140/90 mmHg to 39.6% 
at blood pressure of >140/90 [8]. The relationship in 
children is more complicated as hypertension is relatively 
uncommon and so absolute cut offs can’t be used. Instead 
hypertension is defined with reference to percentiles 
taking into account age. In the NPDA amongst the cohort 
of young people aged 12 years and above with T1D and an 
abnormal eye screening result, 61.5% had above average 
systolic blood pressure, and 93.7% had above average 
diastolic blood pressure [27]. The NPDA also showed 
that all four risk factors – high blood pressure (above 98 
centile), high cholesterol (above 5mmol/mol), high HbA1c 
and obesity were more prevalent in people with abnormal 
DR screening compared to those without.
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Studies have shown that those of African American, 
Hispanic and South Asian origin have an increased risk 
of DR compared to Caucasians [42,43]. The effect of 
dyslipidaemia on DR has been less consistent with the 
DCCT study showing the severity of retinopathy was 
associated with increasing triglycerides and inversely 
associated with HDL cholesterol [44]. However, in the 
in the global meta-analysis by Yau et al. showed higher 
cholesterol levels were associated with a higher prevalence 
of diabetic macular oedema but not diabetic retinopathy 
[8]. The use of fenofibrate has been shown in studies 
to reduce the need for laser therapy however, its affects 
appear to be due to mechanisms other than its lipid 
lowering effects [45,46].
The effect of puberty on DR is difficult to study as it is 
not well recorded and so normally chronological age has 
been used which is a poor marker for puberty. In addition, 
duration of diabetes needs to taken into consideration. 
WESDR used the onset of menarche as the marker for 
puberty and found that duration of diabetes after menarche 
was associated with 30% excess risk of DR compared with 
duration of diabetes before menarche [47]. 
DR has been shown in studies to progress rapidly during 
pregnancy. This may be due to rapid reductions in HbA1c 
levels during pregnancy known as the early worsening 
phenomenon or the release of pregnancy hormones [48, 
49]. Therefore, more frequent screening is recommended 
for women with diabetes who become pregnant depending 
on the level of DR seen [50].
Screening Recommendations
Current recommendations relating to screening for DR 
vary considerably. The National Institute for Clinical 
Excellence (NICE) guideline for diagnosis and management 
of T1D in Children and young people (NG18) suggests 
monitoring for DR from 12 years onwards and annually 
thereafter [11]. There are several guidelines in the US 
which have slightly different recommendations for when 
DR monitoring should begin. The American Academy of 
Ophthalmology currently recommends annual screening 
for all with a duration of diabetes of more than 5 years [51]. 
The American Academy of Paediatrics recommends an 
initial screening 3–5 years after diagnosis of diabetes if over 
age 9 and annually thereafter [52]. Whereas the American 
Diabetes Association recommends that screening begins 
3–5 years after diagnosis of diabetes and once the child 
is 10 years old [53]. The Canadian Diabetes Association 
recommends screening begins 5 years after diagnosis 
in all from the age of 15 years [54]. Whilst, in Europe, 
the International Society for Paediatric and Adolescent 
Diabetes (ISPAD 2018) recommends screening for DR 
from the age of 11[55]. The Retinopathy Working Party 
recommends screening from the onset of puberty [56]. In 
Scandinavia, Finland begin DR screening when patients 
enter puberty [57], and Sweden commence DR screening 
from the age of 10 years [58]. All these recommendations 
are more consensus than evidence based. 
Evidence has also been building since screening began 
for the extension of screening intervals from annual to 
biennial and recently supporting the implementation 
of risk based screening for DR [59-64]. In 2016, the UK 
National Screening Committee (UK NSC) recommended 
biennial screening for those considered to be at low risk of 
progression to sight-threatening DR [65]. The American 
Diabetes Association in 2017, also recommended 
screening to be conducted every 2 years conditional on 
there being no evidence of DR on one or more prior annual 
screening events, with glycaemia well managed and with 
robust information technology systems and support to 
ensure future re-call for screening [66]. However, a recent 
study assessing the cost-effectiveness of extending annual 
screening intervals to biennial in people at low risk of 
developing sight-threatening DR found that for those 
with T1D it was only cost-effective in those with a HbA1c 
<48mmol/mol or a duration of diabetes <5 years [67]. 
When considering the extension of screening intervals, 
the risk of non-attendance at screening needs to be 
understood. In a study of people attending diabetic eye 
screening Wales (DESW) those with diabetes aged 17-32 
were least likely to attend with uptake rates falling below 
the 75% acceptable level.
With evidence from UK screening programmes suggesting 
DR is rare before a duration of diabetes of 5 years and 
the prevalence of DR is approximately 10% in those aged 
12 at first screening [68,69] in addition to the extension 
of screening recommendations, a review of screening 
recommendations for children and young people with T1D 
may be required.
Conclusions
Prevalence of DR in children screened is substantially 
higher than that previously reported and remains a 
significant concern in T1D. It is essential to identify DR 
early on so that steps could be taken to slow the progression 
and or treat it early. Good glycaemic and blood pressure 
management are the cornerstones of both the prevention 
of onset and progression of DR.
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